© 2019 The Authors Objective: To analyze the use, effectiveness, safety and costs of stroke prevention in non-valvular atrial fibrillation (AF) in patients initiating treatment with dabigatran or vitamin K antagonists (VKA). Setting: Primary Care (PC) at the Catalan Health Institute (ICS) in Catalonia, during 2011-2013. Participants: Patients attended in ICS PC centres with a registered diagnosis of AF who initiate dabigatran or VKA. Interventions: Not applicable Main measurements: Number of prescriptions and reimbursements of dabigatran and VKA, incidence of stroke and haemorrhages, incidence of mortatlity, number of sickness leave, and costs associated to all the previous variables. Results: 14,930 patients were included; 94.6% initiated VKA and 5.4%, dabigatran. Dabigatran patients were younger and with less comorbidity. There were no statistically significant differences between VKA and dabigatran in the risk of stroke, haemorrhages or death. The costs associated to AF management were higher for PC visits in the VKA group, and higher for laboratory and pharmacy in the dabigatran group, although overall costs were not statistically different. Conclusions: Most patients initiated VKA. We found no differences between VKA and dabigatran in the risk of stroke, haemorrhages or mortality.
|Journal||Atención primaria (Barcelona. Ed. impresa)|
|Publication status||Published - 1 Jan 2019|
- Atrial fibrillation
- Direct oral anticoagulants
- Vitamin K antagonists